Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

Autor: Marius M. Hoeper, David B. Badesch, H. Ardeschir Ghofrani, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Vallerie V. McLaughlin, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Ekkehard Grünig, Grzegorz Kopeć, Gisela Meyer, Karen M. Olsson, Stephan Rosenkranz, Yayun Xu, Barry Miller, Marcie Fowler, John Butler, Joerg Koglin, Janethe de Oliveira Pena, Marc Humbert

Publikováno v: New England Journal of Medicine. 388:1478-1490

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41d65b90f87f51f23852b01abc7d8fae
https://doi.org/10.1056/nejmoa2213558

Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy

Autor: Jeffrey M. Statland, Craig Campbell, Urvi Desai, Chafic Karam, Jordi Díaz‐Manera, Jeffrey T. Guptill, Lawrence Korngut, Angela Genge, Rabi N. Tawil, Lauren Elman, Nanette C. Joyce, Kathryn R. Wagner, Georgios Manousakis, Anthony A. Amato, Russell J. Butterfield, Perry B. Shieh, Matthew Wicklund, Josep Gamez, Cynthia Bodkin, Alan Pestronk, Conrad C. Weihl, Juan J. Vilchez‐Padilla, Nicholas E. Johnson, Katherine D. Mathews, Barry Miller, Ashley Leneus, Marcie Fowler, Marc van de Rijn, Kenneth M. Attie

Publikováno v: MUSCLE & NERVE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

INTRODUCTION/AIMS: Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive muscular dystrophy without approved therapies. In this study we evaluated whether locally acting ACE-083 could safely increase muscle volume and improve function

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5633f4fbc98d0656df25aa5f60ef8e7f
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=9872

Anti-hyperalgesic effects of AG490, a Janus kinase inhibitor, in a rat model of inflammatory pain

Autor: Thomas H. Garza, Bopaiah P. Cheppudira, Lawrence N. Petz, John L. Clifford, Marcie Fowler

Publikováno v: Biomedical Reports. 3:703-706

Interleukin 6 (IL-6) has a critical role in pain mechanisms. IL-6 signals through the Janus-activated kinases 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) pathway. The contribution of JAK2 signaling in inflammation-induced

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b0bba5c9066a0ee738962fd24f64290
https://doi.org/10.3892/br.2015.497

Activated 5′flanking region of NANOGP8 in a self-renewal environment is associated with increased sphere formation and tumor growth of prostate cancer cells

Autor: Jonathan D. Glass, Marcie Fowler, Hong Yin, Kai Zhang

Publikováno v: The Prostate. 74:381-394

INTRODUCTION NANOGP8 is a retrogene which encodes a full-length protein similar to the NANOG1 gene. The expression of NANOGP8 has been documented in several cancers and is related to cell proliferation and tumor development. However, the regulation o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::021805f163381a15902ac8813c9189eb
https://doi.org/10.1002/pros.22759

Prehospital and en route analgesic use in the combat setting: a prospectively designed, multicenter, observational study

Autor: A. Ervin, Stuart D. Tyner, Alex Mora, Lawrence N. Petz, Vikhyat S. Bebarta, Ed Barnard, Marcie Fowler, John L. Clifford

Publikováno v: Military medicine. 180

Combat injuries result in acute, severe pain. Early use of analgesia after injury is known to be beneficial. Studies on prehospital analgesia in combat are limited and no prospectively designed study has reported the use of analgesics in the prehospi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e609fcb8dbc383130a386bd8345dab2
https://pubmed.ncbi.nlm.nih.gov/25747624